More trials at ESC, including PARACHUTE HF, DAPA ACT HF-TIMI 68, AMALFI, and a super-interesting modeling study of when to start oral anticoagulants in AF, are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I PARACHUTE HF
First Evidence of Treatment Benefit in Chagas Heart Failure
https://www.medscape.com/viewarticle/first-evidence-treatment-benefit-chagas-heart-failure-2025a1000oem
- PARACHUTE-HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021
II SGLT2i Early Initiation — DAPA ACT HF-TIMI 68 Trial
Trial Data Support In-Hospital Initiation of SGLT2 Inhibitors for Heart Failure https://www.medscape.com/viewarticle/trial-data-support-hospital-initiation-sglt2-inhibitors-2025a1000o5q
https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076575
III AMALFI Trial of AF Screening
Remote ECG Screening Ups Atrial Fibrillation Detection ‘Modestly’ https://www.medscape.com/viewarticle/remote-ecg-screening-ups-atrial-fibrillation-detection-2025a1000myx
- AMALFI Trial https://jamanetwork.com/journals/jama/article-abstract/2838482
- STROKESTOP Trial https://www.thelancet.com/article/S0140-6736(21)01637-8/fulltext
- LOOP Trial 10.1016/S0140-6736(21)01698-6 External Link
IV Finding that Sweet Spot of Stroke Risk Threshold for Starting DOAC therapy
- Stroke Risk Threshold for non-Vitamin K Antagonist OAC in AF https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012090
- Variations in Rates of Stroke Across Patients With AF https://www.ahajournals.org/doi/10.1161/circulationaha.116.024057
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
